TDP-43 Proteinopathies

TDP-43 proteinopathies are a group of rare diseases affecting the brain. They are caused by a protein called TDP-43 that gets stuck in nerve cells. This buildup can lead to symptoms like memory loss, difficulty speaking, and muscle problems. These diseases are distinct from others because they don't involve the buildup of amyloid, a type of protein often found in other brain diseases.

Condition

What people with TDP-43 Proteinopathies report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About TDP-43 Proteinopathies

What It Is

TDP-43 proteinopathies are a group of progressive brain and nerve diseases that share one feature: a protein called TDP-43 (TAR DNA-binding protein 43) forms abnormal clumps inside cells of the brain and spinal cord. TDP-43 normally helps cells handle the genetic messages they use to make proteins. When it misbehaves and builds up in the wrong form, nerve cells in the affected areas are damaged and gradually die. The name describes what is found in the brain rather than a diagnosis a person usually receives in a clinic. It links several conditions that can look very different from the outside. Most people with amyotrophic lateral sclerosis (ALS), which weakens the muscles used to move, speak, swallow and breathe, have TDP-43 changes. So do a large share of people with frontotemporal dementia (FTD), which mainly alters behavior, personality or language. A third condition, limbic-predominant age-related TDP-43 encephalopathy (LATE), causes memory loss in older adults, usually over 80, and is often mistaken for Alzheimer's disease. Which symptoms appear depends on which part of the nervous system is affected first, and some people develop features of more than one condition, such as FTD combined with ALS.

Causes & Risk Factors

In most people, the cause is unknown. Nearly all ALS appears without a family history, and the same is true of many cases of FTD and LATE. Researchers do not yet know why TDP-43 starts to clump in one person and not another. A minority of cases are inherited. Changes in a gene called C9orf72 are the most common genetic cause of family forms of both FTD and ALS, and the same change can produce either condition, or both, in members of one family. Changes in the GRN gene lower the amount of a protein called progranulin, which leads to TDP-43 problems and usually to FTD. Changes in the gene that makes TDP-43 itself can also cause family forms of ALS. About 10% of ALS runs in families; for FTD the share is higher. A relative of someone with sporadic (non-inherited) ALS has a slightly raised risk, but most never develop it. For LATE, advancing age is the strongest risk factor. Some common gene variants, including APOE, the variant best known for its link to Alzheimer's, are associated with greater risk, and LATE often occurs alongside Alzheimer's changes in the same brain. These associations raise likelihood; they do not determine who will become ill.

How It's Diagnosed

There is currently no scan or routine test that shows TDP-43 clumps in a living person. Brain MRI can show shrinkage in affected areas but not the protein itself. Confirmation comes from examining brain tissue after death, or, in some inherited cases, from finding a known gene change. In practice, doctors diagnose the condition the person has, and the TDP-43 link is inferred from that. For ALS, a neurologist looks for a pattern of weakness, muscle twitching and changed reflexes that worsens over time, and repeats the examination at intervals. Electromyography (EMG), a test of how nerves and muscles carry electrical signals, and MRI help rule out other conditions that can look similar. For FTD, the assessment includes the person's history and observations from family, tests of behavior, language and thinking, and brain imaging that may show shrinkage of the frontal or temporal lobes, although early scans can look normal. Depression and other psychiatric conditions are considered, because FTD is sometimes mistaken for them. For LATE, researchers proposed clinical criteria in 2025. Progressive memory loss with marked shrinkage of the hippocampus (a memory center deep in the brain) suggests LATE, particularly when tests for amyloid, the protein associated with Alzheimer's, are negative. These criteria are still being validated. When there is a family history of ALS or FTD, genetic counseling and testing may be offered, both to clarify the diagnosis and to inform relatives.

Treatment Options

No treatment yet targets TDP-43 or reverses the damage it causes. Treatment depends on which condition a person has and aims to slow decline where possible, ease symptoms and protect independence and safety. For ALS, riluzole, a tablet that reduces the effect of a nerve-signaling chemical called glutamate, may extend survival by a few months; liquid and dissolving forms help people who have trouble swallowing. Edaravone (Radicava), an antioxidant given by IV infusion or by mouth, has slowed loss of daily function in some people. Much of what makes a difference comes from a coordinated care team: physical, occupational and speech therapy, nutrition support, a feeding tube when eating becomes unsafe, and breathing support such as noninvasive ventilation, a machine that delivers air through a mask, often used at night first. For FTD, no medicine slows the disease. Antidepressants called selective serotonin reuptake inhibitors (SSRIs) are commonly used for impulsive or disinhibited behavior, and low doses of antipsychotic medicines are sometimes used for aggression or delusions, with careful attention to side effects. Speech therapy helps people with language-predominant forms, and caregivers benefit from learning practical ways to respond to behavior changes the person cannot control. For LATE, there is no specific treatment; care focuses on supporting memory and daily function, as in other dementias. Anti-amyloid medicines approved for early Alzheimer's act on amyloid, not TDP-43, which is one reason newer criteria aim to tell LATE apart from Alzheimer's before such treatment is considered. Clinical trials testing therapies aimed at TDP-43 and related genes are ongoing.

What to Expect

All of these conditions progress, but the pace varies widely. In ALS, weakness spreads over time to affect walking, hand use, speech, swallowing and eventually breathing. Most people with ALS die of breathing failure within three to five years of their first symptoms, although about 1 in 10 live 10 years or more. Many keep their memory and reasoning throughout, which means they remain aware of their losses; some develop changes in language or decision-making. In FTD, survival ranges from less than two years to more than 10 years after diagnosis. Early on, a person may show only one type of change, such as poor judgment, loss of empathy or difficulty finding words, and other symptoms appear as the disease spreads. People with FTD often do not recognize their own changes, which can strain relationships and work. When FTD and ALS occur together, decline is usually faster, often over two to three years. LATE generally progresses slowly, with memory loss as the main feature, but the course tends to be quicker when Alzheimer's changes are also present. Across these conditions, planning early lets the person take part in decisions about finances, care and treatment preferences while they can. Caregivers often take on new responsibilities for safety and daily tasks, and support groups, respite care and specialist clinics can ease that load. Regular follow-up lets the care team adjust nutrition, mobility aids, breathing support and medicines as needs change.

When to Seek Help

See a doctor, and ideally a neurologist, about weakness, muscle twitching, slurred speech or clumsiness that keeps getting worse, about a lasting change in personality, behavior, judgment or language, or about memory loss that interferes with daily life. If ALS or FTD runs in your family, a genetic counselor can explain what testing would and would not tell you. For someone already diagnosed with ALS, contact the care team promptly about new shortness of breath, or trouble breathing at night or when lying down, and about frequent choking, coughing during meals or weight loss. For someone with FTD, contact the care team when behavior changes create safety risks at home, on the road or with money.

Questions to Ask Your Doctor

  1. 1.Which condition do my symptoms point to, and how confident can we be without a test for TDP-43?
  2. 2.Would genetic testing be useful for me, and what would the results mean for my relatives?
  3. 3.Which treatments and therapies make sense at this stage, and what can they realistically achieve?
  4. 4.What changes should we prepare for over the next year, and which decisions should we make now?
  5. 5.Are there clinical trials or specialist clinics I should consider?

Last reviewed • Oct 2026

Educational content, not medical advice.